Chinese Flu Shot Prepares to Enter Brazil

Clover Biopharmaceuticals, Ltd. announced today that it has completed the Biologic License Application (BLA) submission for its seasonal influenza vaccine (AdimFlu-S) to the Brazilian Health Regulatory Agency.

Upon approval, Clover will work with its local partner to commercialize AdimFlu-S, a quadrivalent split-inactivated vaccine containing hemagglutinin from four influenza virus strains (A and B).

If approved in Brazil, Clover's AdimFlu-S would have access to the Southern Hemisphere market.

Brazil is a vital vaccine market strategically. The country has the world's second-largest seasonal influenza vaccine market. Its market size is expected to surpass US$1 billion over the next five years.

"The BLA submission of AdimFlu-S in Brazil is another step towards our goal of becoming a global leader in the respiratory vaccine space and builds upon Clover's prior experience enrolling over 10,000 people in clinical trials across Brazil and South America," said Joshua Liang, Chief Executive Officer, and Executive Director of Clover, in a press release on November 6, 2023.

"By leveraging our unique globalization capabilities, we will continue expanding to other countries and regions to diversify our sales and maximize our impact on public health." 

 As of September 2023, AdimFlu-S has been listed in 26 provinces and municipalities in China. 

Clover's diverse pipeline of candidates includes potential treatments that could significantly reduce the burden of vaccine-preventable diseases and make more diseases preventable.  

In the United States, 145.42 million influenza vaccine doses (egg-based, nasal, cell-based) had been distributed in the U.S. as of October 28, 2023,